Evaluation of anti-DFS70 antibodies and DFS pattern in ANA positive individuals and ANA Associated Rheumatic Diseases

Yıl 2021, Cilt: 5 Sayı: 3, 234 - 238, 31.12.2021

Sevcan Uğur , Tuğba Kula Atik

https://doi.org/10.30565/medalanya.952813

Öz

Aim: In this study we aimed to find the frequency of anti-DFS70 antibodies and DFS pattern in ANA positive individuals and ANA associated rheumatic diseases (AARDs).

Methods: In this study, 337 subjects who were evaluated in a rheumatology clinic with prediagnosis of rheumatic diseases with positive ANA test and had concurrent anti-extractable nuclear antigen (anti-ENA) antibodies results were retrospectively analyzed. Clinical diagnosis of patients and demographic characteristics were obtained from the patients' medical records.

Results: A total of 337 subjects (305 women, 32 men) were included in this study. The mean age was 49.8 ± 14.2 years. Of the 337 participants, 111 (32.9%) had an IIF-DFS pattern and 226 (67.1%) had a non-DFS pattern. Anti-DFS70 antibodies were positive in 20.1% of individuals. Sixty eight individuals had AARDs. An IIF-DFS pattern was observed in 22.1% and a non-DFS pattern was observed in 77.9% of individuals with AARDs (p <0.05). Anti-DFS70 antibodies were positive in 13.2% of patients with AARDs. The frequency of AARDs was significantly lower in individuals with anti-DFS70 antibodies compared to individuals with other anti-ENAs antibodies (p <0.05).

Conclusion: Anti-DFS70 antibodies may be present in patients with AARDs but AARDs are less prevalent in patients who had anti-DFS70 antibodies, compared with patients who had other anti-ENAs.

Anahtar Kelimeler

Antinuclear antibodies (ANA, Anti-DFS70 antibody, DFS pattern

ANA Pozitif Bireylerde ve ANA İlişkili Romatizmal Hastalıklarda Anti-DFS70 Antikorlarının ve DFS paterninin Değerlendirilmesi

Öz

Amaç: Bu çalışmada, ANA pozitif bireylerde ve ANA ilişkili romatizmal hastalıklarda anti-DFS70 antikor ve DFS patern sıklığını bulmayı amaçladık.

Yöntem: Bu çalışmada romatoloji kliniğinde romatizmal hastalık ön tanısı ile değerlendirilen, ANA tetkiki pozitif olan ve eş zamanlı anti-ekstrakte edilebilir nükleer antijen (anti-ENA) antikor sonucu olan 337 kişi retrospektif olarak incelendi. Hastaların klinik tanıları ve demografik özellikleri hasta tıbbi kayıtlarından elde edildi.

Bulgular: Bu çalışmaya toplam 337 (305 kadın, 32 erkek) kişi dahil edildi. Yaş ortalaması 49.8±14.2 yıl idi. 337 katılımcının 111’i (%32.9) IIF-DFS paterne, 226’sı (%67.1) DFS dışı paterne sahipti. Bireylerin %20.1’inde anti-DFS70 antikoru pozitifti. 68 kişide ANA ilişkili romatizmal hastalık vardı. ANA ilişkili romatizmal hastalığa sahip kişilerin %22.1’inde IIF-DFS patern, %77.9’unda DFS dışı patern gözlendi (p<0.05). ANA ilişkili hastalığa sahip kişilerin %13.2’sinde anti-DFS70 antikoru pozitifti. Anti-DFS70 antikoruna sahip kişilerde diğer anti-ENA antikorlarına sahip kişilerle karşılaştırıldığında ANA ilişkili romatizmal hastalık sıklığı anlamlı ölçüde düşüktü (p<0,05).

Sonuç: Anti-DFS70 antikorlar ANA ilişkili romatizmal hastalıklarda bulunabilir ancak ANA ilişkili romatizmal hastalıklar anti-DFS70 antikorlarına sahip kişilerde diğer anti-ENA antikorlarına sahip kişilere kıyasla daha az yaygındır.

Anahtar Kelimeler

Anti nükleer antikor (ANA), Anti DFS70 antikor, DFS patern

Kaynakça

• 1. Infantino M, Pregnolato F, Bentow C, Mahler M, Benucci M, Li Gobbi F, et al. Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clin Chem Lab Med. 2019;57(11):1764-9. doi: 10.1515/cclm-2019-0454.
• 2. Meroni PL, Schur PH. ANA screening: An old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420-2. doi: 10.1136/ard.2009.127100.
• 3. Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-16. doi: 10.1007/s12016-016-8564-5.
• 4. Carbone T, Pafundi V, Tramontano G, Gilio M, Padula MC, Padula AA, et al. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Sci Rep. 2019;9(1):2177. doi: 10.1038/s41598-019-38686-5.
• 5. Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a Community Hospital. Front Med (Lausanne). 2018;5:88. doi: 10.3389/fmed.2018.00088.
• 6. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200. doi: 10.1002/art.30084.
• 7. Dellavance A, Viana VST, Leon EP, Bonfa ESDO, Andrade LEC, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32(11):2144-9. PMID: 16265692.
• 8. Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev. 2012;11(9):642-5. doi: 10.1016/j.autrev.2011.11.005.
• 9. Damoiseaux J, von Muhlen CA, Garcia-de la Torre I, Carballo OG, de Melo Cruvinel W, Francescantonio PLC, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016;7(1):1. doi: 10.1007/s13317-016-0075-0.
• 10. Mahler M, Andrade LE, Casiano CA, Malyavantham K, Fritzler MJ. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol. 2019;15(3):241-50. doi: 10.1080/1744666X.2019.1562903.
• 11. Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, GhillaniDalbin P, et al. Clinical phenotypes of patients with anti-DFS70/ LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759. doi: 10.1155/2013/703759.
• 12. Lee H, Kim Y, Han K, Oh EJ. Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells scand. J Rheumatol. 2016;45(2):122-8. doi: 10.3109/03009742.2015.1060260.
• 13. La Jeon Y, Kang SY, Lee WI, Kim MH. Clinical aspects of the dense fine speckled pattern in indirect immunofluorescence-antinuclear antibody screening and its association with DFS70 autoantibodies. Ann Clin Lab Sci. 2019;49(4):496-502. PMID: 31471339.
• 14. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900. doi: 10.1002/art.20096.
• 15. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy ındividuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-10. doi: 10.3899/jrheum.120598.
• 16. Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 2008;17(3):171-6. doi: 10.1177/0961203307086311.
• 17. Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;38(12):3627-33. doi: 10.1007/s10067-019-04730-y.
• 18. Türkoğlu G, Berkem R, Karakoç AE. Investigation of the diagnostic value of anti-dense fine speckled 70/lens epithelium derived growth factor p75 autoantibody for autoimmune diseases. Mikrobiyol Bul. 2018;52(4):413-24. doi: 10.5578/mb.67385.